The global demand for Emphysema Treatment Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Emphysema is a lung disease that involves reduction in the surface area of the lungs which in turn reduces the amount of oxygen reaching the bloodstream. Emphysema and chronic bronchitis are together known as Chronic Obstructive Pulmonary Disease (COPD). The patients who suffer from emphysema also have chronic bronchitis. The major causes of emphysema are exposure to chemical fumes, air pollutants, dust, and smoking. The state can be diagnosed through various tests such as lung function tests and imaging tests that include chest X-ray and CT scan.
Market Dynamics
The rising number of COPD and the asthmatic population worldwide coupled with FDA consent for the novel products and its wide adoption among the patient are the major factors driving the emphysema treatment market over the forecast period. Moreover, the high availability of diagnostic services for respiratory illness and rising government initiatives to control COPD and asthma are highly contributing to the global emphysema treatment market's growth. The technological advancement in the treatment of asthma and COPD and rising pipeline products holds immense potential for the growth of the global emphysema treatment market. Furthermore, increasing research and development in developing effective drugs with growing initiatives implemented by the non-government and government associations for creating health awareness are expected to create a lucrative opportunity for the key players in the coming years.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of emphysema treatment.
Market Segmentation
The entire emphysema treatment market has been sub-categorized into diseases and medication class. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Diseases
By Medication Class
- Combination Products
- Seretide/Advair
- Symbicort
- Relvar/BreEllipta
- Flutiform
- Dulera
- Others
- Leukotriene Antagonists (LTA)
- Inhaled Corticosteroids (ICS)
- Qvar
- Pulmicort
- Aerospan
- Flovent
- Others
- Anticholinergics
- Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for emphysema treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Emphysema Treatment Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the emphysema treatment market include Intrexon Corporation, Pulmonx Inc., Halozyme Therapeutics, Inc., Mariposa Health Limited, PneumRx, Uptake Medical Corporation, Icure Pharmaceuticals, Inc., Pfizer, Inc., BTG International's, Olympus Corporation, Kamada Limited, Emphasys Medical, Inc., Bioxyne Limited. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.